Curriculum Vitae Amy J. Johnson, Ph.D. Associate Professor of Medicine with Tenure OSU CCC Room 455C 410 West 12th Avenue The Ohio State University Columbus, Ohio 43210 amy.johnson@osumc.edu Tel: 614-685-2341 Fax: 614-292-3312 Lab Website: cll.osu.edu

Education Ph.D., Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky

August 1997 to May 2002 B.A., Biological Sciences, DePauw University, Greencastle, Indiana

August 1993 to May 1997

Professional Experience Associate Professor of Medicine, Division of Hematology, College of Medicine The Ohio State University, Columbus, Ohio CLL Experimental Therapeutics Laboratory November, 2013 to present Research Assistant Professor, Division of Hematology and Oncology College of Medicine, The Ohio State University, Columbus, Ohio CLL Experimental Therapeutics Laboratory

December, 2007 to November, 2013 Research Scientist, Division of Hematology and Oncology College of Medicine, The Ohio State University, Columbus, Ohio Laboratory of John Byrd, M.D.

June, 2005 to December, 2007 Post-Doctoral Researcher, Division of Hematology and Oncology,

College of Medicine, The Ohio State University, Columbus, Ohio Mentor: John Byrd, M.D. June, 2002 to May, 2005

Visiting Scholar, Division of Medicinal Chemistry and Pharmacognosy

College of Pharmacy, The Ohio State University, Columbus, Ohio Mentor: Ching-Shih Chen, Ph.D. May, 2001 to June, 2002

Teaching Assistant, Division of Pharmaceutical Sciences College of Pharmacy, University of Kentucky, Lexington, Kentucky Mentor: Ching-Shih Chen, Ph.D. August, 1997 to May, 2001

Summer Intern, Lilly Research Laboratories

Eli Lilly and Company, Indianapolis, Indiana Mentor: Marlene Cohen, Ph.D. Summers 1995 and 1996

Updated 04/15/16

2

Society Membership American Association of Cancer Research American Society of Hematology European Hematology Association American Society of Clinical Oncology

Honors and Awards American Cancer Society-IDEC/Genentech/Ronald Levy Postdoctoral Fellowship, 2003-06 ASPET Graduate Student Travel Award, 2000 and 2002 ASPET Research Fellowship, 1996 Howard Hughes Foundation Summer Fellowship, 1995 Peer Reviewed Publications (94 total, 24 senior or co-senior author) *indicates authors contributed equally

1. Johnson AJ, Song X, Hsu AL, Chen CS. (2001) “Apoptosis Signaling Pathways Mediated by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells”. Adv. Enzyme Regul., 41:221-235.

2. Ching TT, Hsu AL, Johnson AJ, Chen CS. (2001) “Phosphoinositide 3-Kinase Facilitates Antigen-Stimulated Ca2+ Influx in RBL-2H3 Mast Cells via a Phosphatidylinositol 3,4,5-Trisphosphate-Sensitive Ca2+ Entry Mechanism”. J. Biol. Chem., 276:14814-14820.

3. Johnson AJ, Hsu AL, Song X, Lin HP, Chen CS. (2002) “The Cyclooxygenase-2 Inhibitor Celecoxib Perturbs Intracellular Calcium by Inhibiting Endoplasmic Reticulum Ca2+-ATPases. A Plausible Link with Its Antitumor effect and Cardiovascular Risks”. Biochem. J., 367, 791-9.

4. Song X, Lin HP, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS. (2002) “Cyclooxygenase-2, Player or Spectator in Cyclooxygenase-2 Inhibitors-Induced Apoptosis in Prostate Cancer Cells”. J. National Cancer Institute, 94:585-591.

5. Johnson AJ, Mone AP, Abhyankar V, Byrd JC. (2003) “Advances in the therapy of chronic lymphocytic leukemia”. Curr Opin Hematol, 10:297-305.

6. Mone A, Huang P, Pelicano H, Cheney CM, Green JM, Tso JY, Johnson AJ, Jefferson S, Lin TS, Byrd JC. (2004) “Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells”. Blood, 103:1846-1854.

7. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, Bembea M, Liu TH, Heerema NA, Rassenti L, Liyanarachchi S, Davuluri R, Byrd JC, Plass C. (2004) “Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets”. Cancer Res, 64:2424-33.

8. Johnson AJ, Smith LL, Zhu J, Heerema NA, Guster S, Mone A, Grever M, Chen CS, Byrd JC. (2005) “A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism”. Blood, 105:2504-9.

9. Johnson AJ, Lucas DM, Muthusamy N, Smith L, Edwards R, De Lay M, Croce CM, Grever MR, Byrd JC. (2006) “Characterization of the TCL-1 transgenic mouse as a pre-clinical drug development tool for human chronic lymphocytic leukemia”. Blood, 108:1334-8.

10. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. (2007), “Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity”, Clin Cancer Res. 13:2144-50.

11. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. (2007), “Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia”, Blood. 109:399-404.

Updated 04/15/16

3

12. Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. (2007) “Rituximab and 17-allylamino-17-demethoxygeldanamycin (17-AAG) Induce Synergistic Apoptosis in B-Cell Chronic Lymphocytic Leukemia”, Br J Haematology, 139:837-44.

13. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. (2007) “Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia”, Leuk Res. 31:1737-40.

14. Grever MR, Lucas DM, Johnson AJ, Byrd JC. (2007) “Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia”, Best Pract Res Clin Haematol. 20:545-56.

15. Zhang S, Suvannasankha A, Crean CD, White VL, Johnson AJ, Chen C-S, Farag SS. (2007) “OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms”, Clin Cancer Res. 13:4750-4758.

16. Hussain SR, Lucas DM, Johnson AJ, Lin TS, Bakaletz AP, Dang VX, Viatchenko-Karpinski S, Ruppert AS, Byrd JC, Kuppusamy P, Crouser ED, and Grever MR. (2008) “Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium”, Blood. 111:3190-99.

17. Andritsos LA*, Johnson AJ*, Lozanski G, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, May SE, Raymond CA, Wang DS, Knight RD, Ruppert AS, Lehman A, Jarjoura D, Chen CS, Byrd JC. (2008) “Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia”, J Clin Oncol. 26(15):2519-25.

18. Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. (2008). “Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug”, J Clin Invest. 118(7):2427-37.

19. Lapalombella R, Yu B, Triantafillou G, Liu Q, Butchar JP, Lozanski G, Ramanunni A, Smith LL, Blum W, Andritsos L, Wang DS, Lehman A, Chen CS, Johnson AJ, Marcucci G, Lee RJ, Lee LJ, Tridandapani S, Muthusamy N, Byrd JC. (2008) “Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells”, Blood. 112(13):5180-9.

20. Liu Q, Farley KL, Johnson AJ, Muthusamy N, Hofmeister CC, Blum KA, Schaaf LJ, Grever MR, Byrd JC, Dalton JT, Phelps MA. (2008) “Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma”, Ther Drug Monit. 30(5):620-27.

21. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL, Wu D, Blum KA, Fischer B, Mitchell SM, Moran ME, Booker-McEldowney M, Heerema NA, Jarjoura D, Schaaf LJ, Byrd JC, Grever MR, Dalton JT. (2009) “Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia”, Blood. 113(12):2637-45.

22. Lucas DM, Edwards RB, Lozanski G, West D, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, and Grever MR. (2009) “The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo”. Blood. 113(19):4656-4666.

23. Blum KA, Hamadani M, Phillips GS, Lozanski G, Johnson AJ, Lucas DM, Smith LL, Baiocchi R, Lin TS, Porcu P, Devine SM and Byrd JC. (2009) “Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma”, Leukemia and Lymphoma, 50(3):349-56

24. Johnson AJ. (2009) “Mighty mouse” Blood, 114(1):3. (Inside Blood). 25. Chen S-S, Raval A, Johnson AJ, Hertlein E, Liu T-H, Jin VX, Sherman MH, Liu S, Dawson DW,

Williams KE, Lanasa M, Liyanarachchi S, Lin TS, Marcucci G, Pekarsky Y, Davuluri R, Croce CM, Guttridge DC, Teitell MA, Byrd JC, and Plass C. (2009) “Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia.” PNAS. 106(32):13433-8.

26. Lapalombella R, Gowda A, Joshi T, Mehter N, Cheney C, Lehman A, Chen CS, Johnson AJ, Caligiuri MA, Tridandapani S, Muthusamy N, and Byrd JC. (2009) “The humanized CD40 antibody

Updated 04/15/16

4

SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukemia”. Br J Haematol. 144(6):848-55.

27. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, Blum KA, Flynn JM, Jones JA, Hu W, Moran ME, Mitchell SM, Smith LL, Wagner AJ, Raymond CA, Schaaf LJ, Phelps MA, Villalona-Calero MA, Grever MR, and Byrd JC. (2009) “Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease.” J. Clin. Oncol. 27(35):6012-8.

28. Chen SS, Sherman MH, Hertlein E, Johnson AJ, Teitell MA, Byrd JC, and Plass C. (2009) “Epigenetic alterations in a murine model for chronic lymphocytic leukemia”. Cell Cycle. 8(22):3663-7.

29. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P, Kraut EH, Baiocchi RA, Moran ME, Johnson AJ, Schaaf LJ, Grever MR and Byrd JC. (2010) “Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders”. J. Clin. Oncol. 28(3):418-23.

30. Awan FT, Johnson AJ, Lapalombella R, Hu W, Lucas M, Fischer B, and Byrd JC. (2010) “Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia”. Leuk Lymphoma. 51(1):27-38.

31. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R, Jr, Rader C, Muthusamy N, Johnson AJ*, and Byrd JC*. (2010) “Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B Cells through a PI3-kinase dependent pathway”. Blood. 115(13):2619-2629.

32. Hertlein E, Wagner AJ, Jones J, Lin TS, Maddocks KJ, Towns WH III, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Croce CM, Byrd JC, and Johnson AJ. (2010), “17-DMAG targets the NF- B family of proteins to induce apoptosis in CLL: clinical implications of HSP90 inhibition”. Blood. 116(1):45-53.

33. Blum W, Phelps MA, Klisovic RB, Rozewski DM, Ni W, Albanese KA, Rovin B, Kefauver C, Devine SM, Lucas DM, Johnson AJ, Schaaf LJ, Byrd JC, Marcucci G, Grever MR. (2010), “Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias”. Haematologica. 95:1098-1105.

34. Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones JA, Andritsos L, Puri KD, Lannutti BJ, Giese NA0, Zhang X, Wei L, Byrd JC, Johnson AJ. (2010), “Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals”. Blood. 116:2078-208.

35. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, Wang D, Lehman A, Zhang X, Jarjoura D, Kulp SK, Croce CM, Grever MR, Chen CS, Baiocchi RA, Byrd JC. (2010) “The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo”. PLoS One. 5(6):e10941.

36. Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Linn TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA. (2010), “Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition.” PLoS One. 5(11)e13792.

37. Chen SS, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, West DA, Williams KE, Johnson AJ, Sablitzky F, Plass C, Byrd JC. (2010), “Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL”. Blood. 117(3):862-71.

38. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM, Deininger M, Druker BJ, Puri KD, Ulrich RG, Giese NA. (2011), “CAL-101, a p110 {delta} selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability”. Blood. 117:591-594.

39. Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ. (2011), “The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia”. Blood. 117:4323-4327.

Updated 04/15/16

5

40. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ*, Byrd JC*. (2011), “Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765”. Blood. 117:6287-6296.

41. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. (2011), “Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol”. Leukemia. 25(9):1444-51.

42. Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA. (2011), “Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein”. J Clin Oncol. 29(25):3427-34.

43. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC, Croce CM, Jacob ST. (2011), AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. Blood. 118:6132-6140.

44. Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Heerema NA, Byrd JC. (2012), “Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features”. Leukemia. 2012; 26(6):1442-4.

45. Byrd JC, Woyach JA, Johnson AJ. Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101). American Society of Clinical Oncology educational book / ASCO. 2012; 691-4.

46. Stephens DM, Ruppert AS, Blum K, Jones J, Flynn JM, Johnson AJ, Ji J, Phelps MA, Grever MR, Byrd JC. (2012), “Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach”. Haematologica. 97:423-427.

47. Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC, Williams DA. (2012) “Rohr is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.” Blood. 119:4708-4718.

48. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE, Johnson AJ, Lozanski A, Andritsos L, Jones J, Flynn JM, Lannutti B, Thompson P, Algate P, Stromatt S, Jarjoura D, Mo X, Wang D, Chen CS, Lozanski G, Heerema NA, Tridandapani S, Freitas MA, Muthusamy N, Byrd JC. (2012) Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Cancer Cell. 21(5):694-708.

49. Johnson AJ and Sarah E.M. Herman. (2012) “Molecular Pathways: Targeting the Phosphoinositide 3-Kinase (PI3-Kinase) p110 delta in Chronic Lymphocytic Leukemia.” Clin. Cancer Res. 18:4013-4018.

50. Woyach JA, Johnson AJ, Byrd JC. (2012) “The B-cell receptor signaling pathway as a therapeutic target in CLL.” Blood. 120:1175-1184.

51. Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SEM, Smith LL, Yeh Y-Y, Andritsos LA, Jones JA, Flynn JM, Blum KA, Zhang X, Lehman A, Kong H, Gurcan M, Grever MR, Johnson AJ*, Byrd JC*. (2012) “ER stress and autophagy: new players in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor Flavopiridol.” Blood. 120:1262-1273.

52. Rozewski DM, Herman SE, Towns WH 2nd, Mahoney E, Stefanovski MR, Shin JD, Yang X, Gao Y, Li X, Jarjoura D, Byrd JC, Johnson AJ*, Phelps MA*. (2012) “Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice.” AAPS J., 872-882.

53. Lapalombella R, Sun Q, Williams K, Tangeman L, Jha S, Zhong Y, Goettl V, Mahoney E, Berglund C, Gupta S, Farmer A, Mani R, Johnson AJ, Lucas DM, Mo X, Daelemans D, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Chook YM, Byrd JC. (2012) “Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.” Blood. 120:4621-4634.

Updated 04/15/16

6

54. Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC. (2012) “The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. “ Leukemia. 26(12):2554-7.

55. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, His ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd KC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. (2013) “Genetic heterogeneity of diffuse large B-cell lymphoma.” PNAS. 110:1398-1403.

56. Ji J, Mould DR, Blum KA, Ruppert AS, Poi M, Zhao Y, Johnson AJ, Byrd JC, Grever MR, Phelps MA. “A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol.” (2013) Clin. Cancer Res. 19:1269-1280.

57. Mahoney E, Byrd JC, Johnson AJ. “Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.” Autophagy. 2013 Mar 1;9(3):434-5.

58. Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJ. “Identification Of Endoplasmic Reticulum Stress Inducing Agents By Antagonizing Autophagy: A New Potential Strategy For Identification Of Anti-Cancer Therapeutics In B-Cell Malignancies.” Leukemia Lymphoma 2013; 54(12):2685-92.

59. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. “Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.” N Engl J Med 2013 July 4; 369(1):32-42.

60. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM. “Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia”. Leuk Res. 2013 37(10):1195-9.

61. Hertlein E, Beckwith KA, Lozanski G, Chen TL, Towns WH, Johnson AJ, Lehman A, Ruppert AS, Bolon B, Andritsos L, Lozanski A, Rassenti L, Zhao W, Jarvinen TM, Senter L, Croce CM, Symer DE, de la Chapelle A, Heerema NA, Byrd JC. Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease. PLoS One. 2013 Oct 9;8(10).

62. Harshman SW, Chen MM, Branson OE, Jacob NK, Johnson AJ, Byrd JC, Freitas MA. Isolation and analysis of linker histones across cellular compartments. J Proteomics. 2013 Oct 8;91:595-604.

63. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ*, Byrd JC*. “Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes”. Blood. 2013 122:2539-2549.

64. Dubovsky JA, Chappell DL, Harrington BK, Agrawal K, Andritsos LA, Flynn JM, Jones JA, Paulaitis ME, Bolon B, Johnson AJ, Byrd JC, Muthusamy N. “Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing”. Blood. 2013 122:3308-3316.

65. Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC*, Johnson AJ*. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). Blood 2014 Feb 20;123:1207-1213.

66. Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ*, Phelps MA*. Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. J Pharm Biomed Anal. 2014 Jan;88:262-8.

Updated 04/15/16

7

67. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: an open-label, multicenter, phase 1b/2 trial. Lancet Oncol. 2014 Jan;15(1):48-58.

68. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas DM, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones JA, Flynn JM, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ*, Byrd JC*. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014 Mar 20;123:1810-1817.

69. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. Leukemia. 2014 Jun;28(6):1365-8.

70. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R*, Johnson AJ*, Byrd JC*. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood. 2014 Mar 20;123(12):1957-60.

71. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol. 232(19):2067-73.

72. Woyach JA, Furman RR, Lie T-M, Pze JG, Zapatka, Ruppert AS, Xue L, Li D, Steggerda SM, Verselle M, Dave SS, Zhang J, Yilmaz AS, Jaglowski S, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos J, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY*, Johnson AJ*, Byrd JC*. Resistance Mechanisms for the Bruton’s Tyrosine Kinase Inhibitor Ibrutinib. New Eng J Med. 2014 Jun 12;370(24):2286-94.

73. Pierceall WE, Warner SL, Lena RJ, Doykan C, Blake N, Elashoff M, Von Hoff D, Bearss DJ, Cardone MH, Andritsos L, Byrd JC, Lanasa MC, Grever MR, Johnson AJ. (2014) “Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response”. Leukemia. 2014 Nov;28(11):2251-4.

74. Maddocks K, Ruppert AS, Browning R, Jones J, Flynn J, Kefauver C, Gao Y, Jiang Y, Rozewski DM, Poi M, Phelps MA, Harper E, Johnson AJ, Byrd JC, Andritsos LA. A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. Leuk Res. 2014 Sep;38(9):1025-9.

75. Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. (2014) “Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician”. J Clin Oncol. 2014 Sep 20;32(27):3039-47.

76. Chiron D, DiLiberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K. Ali S, Johnson AJ, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S. (2014) “Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma”. Cancer Discovery 2014 Sep; 4(9):1022-35.

77. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ. “IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.” Blood. 2014; Dec. 4; 124:3583-3586.

78. Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ*, Byrd JC*. “miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib.” Leukemia. 2015; 29(5):1210-3.

79. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S. Serody JS, Muphy WJ, Munn DH, Luznik L, Hill Gr, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J,

Updated 04/15/16

8

Panoskaltsis-Mortari A, Byrd JC, Blazer BR. Ibrutinib treatment ameliorates murine chronic graft versus-host disease. J. Clin. Invest. 2014 Nov 3;124(11):4867-76

80. Flynn JM, Jones JA, Johnson AJ, Andritsos LA, Maddocks K. Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. "Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia." Leukemia. 2015; 29(7):1524-9.

81. Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K, MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ. OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. Blood, 2015 Jan 8;125(2):284-95.

82. Zhong Y, Dong S, Strattan E, Ren L, Butchar JP, Thornton K, Mishra A, Porcu P, Bradshaw MJ, Bisconte A, Owens TD, Verner E, Brameld KA, Funk JO, Hill RJ, Johnson AJ*, Dubovsky JA*. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694. J. Biol. Chem. 2015; 290(10):5960-78.

83. Maddocks K, Wei L, Rozewski D, Jiang Y, Zhao Y, Adusumilli M, Pierceall WE, Doykin C, Cardone MH, Jones JA, Flynn J, Andritsos LA, Grever MR, Byrd JC, Johnson AJ, Phelps MA, Blum KA. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL). Am J Hematol. 2015; 90(4):327-33.

84. Lanasa MC, Andritsos L, Brown JR, Gabrilove J, Caligaris-Cappio F, Ghia P, Larson RA, Kipps TJ, Leblond V, Milligan DW, Janssens A, Johnson AJ, Heerema NA, Buhler A, Stilgenbauer S, Devin J, Hallek M, Byrd JC, Grever MR. Final results of EFC 6663: A multicenter, international, phase 2 study of Alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. Leukemia Research. 2015; 39(5):495-500.

85. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16):2497-506.

86. Yeh YY, Chen R, Hessler J, Mahoney E, Lehman AM, Heerema NA, Grever MR, Plunkett W, Byrd JC, Johnson AJ. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Oncotarget. 2015 Feb 20;6(5):2667-2679.

87. Hing ZA, Mantel R, Beckwith KY, Guinn D, Williams E, Smith LL, Williams K, Johnson AJ, Lehman AM, Byrd JC, Woyach JA, Lapalombella R. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015 April 2; 125:3128-3132.

88. Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, gamma 2 acquired in Ibrutinib resistant CLL confers BTK independency upon BCR activation. Blood. 2015; 126(1):61-8.

89. Yeh YY, Ozer HG, Lehman AM, Maddocks K, Yu L, Johnson AJ*, Byrd JC*. Characterization of CLL Exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015 May 21;125(21):3297-305.

90. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients with Chronic Lymphocytic Leukemia. JAMA Oncol. 2015 Apr 1;1(1):80-7.

91. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and Activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015 Aug 13;126(7):842-50.

92. Woyach JA, Johnson AJ. Targeted therapies in CLL: mechanisms of resistance and strategies for management. Blood. 2015 Jul 23;126(4):471-7.

Updated 04/15/16

9

93. Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ*, Furman RR*. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. New Eng J Med. 2015 Dec 7.

94. Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zhaohui Z, Barrett DM, Lacey SF, Melenhorst JJ, McGettigan SE, Cook DR, Zhang C, Xu J, Do P, Hulitt J, Kudchodkar SB, Cogdill AP, Gill S, Porter DL, Woyach JA, Long M, Johnson AJ, Maddocks K, Muthusamy N, Levine BL, June CH, Byrd JC, Maus MV. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Jan 26:10.1182/blood-2015-11-679134.

Advising Current Graduate Students

2012 – present Daphne Guinn, Doctoral Student, PhD Candidate The Ohio State University, College of Medicine, Integrated Biomedical

Science Graduate Program (IBGP) Co-advisor Research 2013 – present Shuai Dong, Doctoral Student, PhD Candidate

The Ohio State University, College of Medicine, Molecular, Cellular and Developmental Biology (MCDB) Co-advisor Research

2013 – present Bonnie Harrington DVM, Doctoral Student, Pre Candidacy The Ohio State University, Department of Veterinary Biosciences in the College of Veterinary Medicine, Anatomic Pathology Residency/PhD Program Co-advisor Research

2014 - present Zachary Abrams, Doctoral Student, PhD Candidate The Ohio State University, College of Medicine, Biomedical

Science Graduate Program (BSGP) Dissertation Advising Committee

2015 - present Rebecca Kohnken, Doctoral Student, Pre Candidacy The Ohio State University, Department of Veterinary Biosciences in the College of Veterinary Medicine, Anatomic Pathology Residency/PhD Program

Dissertation Advising Committee Current Post-Doctoral

2016 - present Sara El-Gamal, Post-doctoral Researcher

Mentoring History Graduate Students 2008 - 2010 Sarah May Herman, PhD

Updated 04/15/16

10

The Ohio State University, College of Medicine, Integrated Biomedical Science Graduate Program (IBGP) Co-advisor Research

2009 – 2012 Darlene Rozewski, PhD The Ohio State University, College of Pharmacy, Division of Pharmaceutics Graduate Program Co-advisor Research

2011 – 2014 Ta-Ming Liu, PhD

The Ohio State University, College of Medicine, Molecular, Cellular, and Developmental Biology (MCDB)

Co-advisor Research 2012 - 2015 Yuan Zhao, PhD

The Ohio State University, College of Pharmacy, Division of Pharmaceutics Dissertation Advising Committee Post Doctoral 2010 – 2011 Kami Maddocks, MD, Fellow The Ohio State University, College of Medicine, Divisions of Hematology and Oncology Co-advisor Research

2011 – 2012 Jennifer Woyach, MD, Fellow The Ohio State University, College of Medicine, Divisions of Hematology and Oncology Co-advisor Research

2009 – 2013 Emilia Mahoney, MD, PhD, Post-doctoral Researcher The Ohio State University, College of Medicine, Division of Hematology and Oncology Co-advisor Research

2011 – 2015 Yuh-Ying Yeh, PhD, Post-doctoral Researcher The Ohio State University, College of Medicine Co-advisor Research Editorial Activities Ad Hoc Journal Referee 2008 Blood 2008 Leukemia and Lymphoma 2010 Blood Cells, Molecules and Diseases 2011 Expert Opinion on Investigational Drugs 2013 Pharmaceutical Research

2013 Leukemia 2014 Nature Reviews Cancer

Updated 04/15/16

11

2014 Cancer Investigation 2014 Autophagy 2014 Haematologica Journal Editor 2014 Leukemia Section Editor Abstract Reviewer 2009 American Society of Hematology, Molecular Pharmacology 2010 American Society of Hematology, Molecular Pharmacology 2012 American Society of Hematology, CLL Biology Grant Reviewer 2011 French National Cancer Institute 2012 Paracelsus Private Medical University of Salzburg 2013 Cancer Research UK 2013 Austrian Science Fund 2013 and 2014 Italian Association for Cancer Research

2013 Leukemia and Lymphoma Society Quest for Cures 2013 French National Cancer Institute 2013 Paracelsus Private Medical University of Saltzburg 2013 Leukemia & Lymphoma Society, Quest for Cures 2014 Austrian Science Fund (FWF) 2014 Population Science The Ohio State University IRP Review 2014 Clinical/Translational Science The Ohio State University IRP Review,

The Ohio State University 2015 Leukemia and Lymphoma Society Translational Research Program 2015 KL2 and Davis-Bremer Study Section committee member,

The Ohio State University, Center for Clinical & Translational Science 2016 American Cancer Society, Leukemia, Immunology and Blood Cell Development

Peer Review Grant Application Review Panel 2016 - 2019 American Cancer Society, Peer Review Committee, Standing Member

Comprehensive Cancer Center (CCC) Appointments 2005 – 2013 Member, Experimental Therapeutics Program Comprehensive Cancer Center, The Ohio State University

2013 – present Member, Leukemia Research Program Comprehensive Cancer Center, The Ohio State University University Committees 2014 – present Tenure Track Appointments, Promotion & Tenure Committee Department of Internal Medicine, The Ohio State University

Updated 04/15/16

12

2014 – present Admissions Committee, The Ohio State University,

College of Medicine 2014 – present Admissions Committee, Medical Scientist Training Program, The Ohio State University, College of Medicine Scientific Advisory Boards

2014 Janssen Pharmaceuticals, B-cell Malignancies and B-cell Receptor Resistance Global Advisory Board, Milan, Italy

2015-present Eutropics Pharmaceuticals Service to National/Professional Organizations 2014 Leukemia and Lymphoma

Society Man and Woman of the Year Panel Discussion

2015 XVI International Workshop on Chronic Lymphocytic Leukaemia 2015 Session Chair: B-cell Receptor – BTK, PI3K and Multi-molecular BCR inhibitors

Patents & Inventions

2015 – Compositions and methods for increasing drug efficacy in cancer. John Byrd, Amy Johnson, Emilia Mahoney, David Lucas, Michael Grever. Application # 13/883,862, Patent Issue # 9,044,474, Document Identifier: 61411236.

Presentations Johnson AJ, Lucas DM, Smith LL, Allison JMS, Lin TS, Grever MR, Byrd JC. “Clinical rebirth of flavopiridol in

chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic measurements to improve efficacy and interrogate relevant mechanisms of action,” April 2005, American Association of Cancer Research Annual Meeting, Minisymposia Oral Presentation.

Johnson AJ, Edwards R, Smith LL, Lucas DM, Croce CM, Muthusamy N, Chen C-S, Liu Z, Chan K, Grever MR, and Byrd JC. “The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia”, December 2005, American Society of Hematology Annual Meeting, Oral Presentation.

Johnson AJ, Smith LL, Raymond CA, Lucas DM, Flynn JM, Abu T, Malaz A, Statkevich P, Bannerji, R, Byrd JC. “The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia”, April 2009, American Association of Cancer Research Annual Meeting, Minisymposia Oral Presentation.

Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC. “Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines”. December 2010, American Society of Hematology Annual Meeting, Oral Presentation.

Johnson AJ, “The role of CDK and PI3 kinase inhibitors in CLL”. VIIIth International Workshop of the German CLL Study Group in Cologne. Cologne, Germany, September 4, 2010. Oral Presentation.

Updated 04/15/16

13

Johnson AJ, “CAL-101, a selective inhibitor of the p110 delta isoform of phosphatidylinositol 3-kinase, effective induces apoptosis in chronic lymphocytic leukemia cells providing a novel therapy strategy”. NCI Translational Science Meeting, Washington DC, July 28, 2011. Oral Presentation.

Johnson AJ, “Novel signaling inhibitors of CDK and PI3K”. CLL Research Consortium Annual Meeting, San Diego, CA, April 26, 2013. Oral Presentation.

Johnson AJ, “Novel therapies in CLL”. International Association for Comparative Research on Leukemia and Related Diseases Symposium, Torino, Italy, September 13, 2013. Oral Presentation.

Johnson AJ, "Mechanisms of resistance of kinase inhibitors and how to prevent this." International Workshop on CLL, Cologne Germany, September 10, 2013. Oral Presentation.

Johnson AJ, “Targeting the B-cell receptor in Chronic Lymphocytic Leukemia,” Moffitt Cancer Center, Tampa, FL, October 25, 2013. Oral Presentation.

Johnson AJ, “Targeting the B-cell receptor in Chronic Lymphocytic Leukemia,” The Ohio State University College of Veterinary Medicine, Columbus, Ohio, December 13, 2013. Oral Presentation.

Johnson AJ, “Mechanisms of resistance of kinase inhibitors in CLL.” 1st Annual Chronic Lymphocytic Leukemia Summit, Whistler, British Columbia, March 29, 2014. Oral presentation.

Johnson AJ, “When the clinic meets the laboratory – correlative studies and how to collaborate with scientists. The Ohio State University, Divisions of Hematology and Medical Oncology T32 fellow tutorial, September 3, 2014. Oral Presentation.

Johnson AJ, “Targeting the B-cell receptor in Chronic Lymphocytic Leukemia,” The Ohio State University, Comprehensive Cancer, Columbus, Ohio, Grand Rounds Speaker, October 17, 2014. Oral Presentation.

Johnson AJ, “Targeting the B-cell receptor in Chronic Lymphocytic Leukemia,” Memorial Sloan-Kettering Cancer Center Hematology/Oncology Grand Rounds Speaker, April 7, 2015. Oral Presentation.

Johnson AJ, “Targeting the B-cell receptor in Chronic Lymphocytic Leukemia,” Mayo Clinic, Department of Hematology Grand Rounds, July 23, 2015. Oral Presentation.

Johnson AJ, “Using the TCL1 mouse model for preclinical drug development in Chronic Lymphocytic Leukemia.” Mayo Clinic, Department of Immunology Grand Rounds, July 23, 2015. Oral Presentation.

Johnson AJ, “Mechanisms of action and resistance of CLL novel agents.” 11th Canadian CLL Research Meeting, October 1, 2015. Oral Presentation.

Johnson AJ, “P13-Kinase Inhibitor Resistance”. CLL Research Consortium Annual Meeting, La Jolla, CA, February 24, 2016. Oral Presentation.

Abstracts

1. Johnson AJ, Hsu AL, Song X, Ching TT, Chen CS. Induction of Apoptosis by Cyclooxygenase-2 Inhibitors in Prostate Cancer Cells. FASEB J, 14(8), A1517, 2002.

2. Johnson AJ, Song X, Lin HP, Chen CS. Is Cyclooxygenase-2 a Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells? FASEB J, 16(4), E31, 2002.

3. Mone AP, Lucas D, Aron J, Cheney C, Johnson AJ, Bains SK, Tso JY, Weiner G, Green J, Grever M, Byrd JC. Hu1D10 Induces Parallel Death and Survival Signals in Chronic Lymphocytic Leukemia (CLL) Cells: Justification for Combination Studies of Hu1D10 with PI3 Kinase Inhibitors, ASH, 2002.

4. Johnson AJ, Eisenbeis CF, Cheney CM, Mone AP, Lucas DM, Byrd JC, Rituximab and 17-AAG Synergistically Induce Apoptosis in B-Cell Chronic Lymphocytic Leukemia (CLL), ASH, 2003.

5. Mone AP, Cheney C, Huang P, Pelicano H, Green J, Tso JY, Johnson AJ, Byrd JC. Hu1D10 Activates Both Death and Survival Pathways in Primary Human Chronic Lymphocytic Leukemia Cells: Hu1D10 Induced Reactive Oxygen Species Activate the AKT Survival Pathway, ASH, 2003.

6. Johnson AJ, Smith L, Zhu J, Heerema N, Guster S, Mone A, Grever M, Chen CS, Byrd JC. A Novel Celecoxib Derivative, OSU03012, Induces Cytotoxicity in Primary CLL Cells and Transformed B-Cell Lymphoma Via a Caspase and Bcl-2 Independent Mechanism, ASH, 2004.

7. Johnson AJ, Lucas DM, Smith LL, Allison JMS, Lin TS, Grever MR, Byrd JC. Clinical rebirth of flavopiridol in chronic lymphocytic leukemia (CLL): Utilizing in vitro and in vivo pharmacodynamic

Updated 04/15/16

14

measurements to improve efficacy and interrogate relevant mechanisms of action, AACR 2005, Minisymposia Oral Presentation.

8. Johnson AJ, Edwards R, Smith LL, Lucas DM, Croce CM, Muthusamy N, Chen C-S, Liu Z, Chan K, Grever MR, and Byrd JC. The TCL-1 Transgenic Mouse Is an Effective Tool for Pre-Clinical Drug Development in Chronic Lymphocytic Leukemia, December 2005, American Society for Hematology Annual Meeting, Atlanta, Georgia, (Oral Presentation).

9. Edwards RB, Lucas DM, Lozanski G, Johnson AJ, Su B, Lin TS, Byrd JC, Kinghorn AD, Grever MR. “Silvestrol, a Rocaglate Derivative from the Indonesian Plant Aglaia foveolata, Has Significant Bcl-2- and p53-Independent Anti-Tumor Activity against Chronic Lymphocytic Leukemia Cells”, American Society of Hematology, 2006.

10. Lucas DM, Hussain SA, Johnson AJ, Smith LL, Wagner AJ, Allison JM, Guster SE, Lin TS, Byrd JC, Julian MW, Crouser ED, Grever MR, “Flavopiridol Decreases Mcl-1 and Initiates Early Mitochondrial Damage in Chronic Lymphocytic Leukemia (CLL) Cells”, American Society of Hematology, 2006.

11. Blum W, Klisovic RB, Kefauver C, Johnson AJ, Phelps M, Dalton JT, Lucas DM, Huynh L, Liu S, Grever MR, Colevas AD, Marcucci G, and Byrd JC, “Updated Results of a Phase I Study of Flavopiridol in Acute Leukemias Using a Novel, Pharmacokinetically Derived Schedule: Clinical Activity Including Hyperacute Tumor Lysis Syndrome (TLS), Pharmacokinetics (PK), and Pharmacodynamics (PD)”, American Society of Hematology, 2006.

12. West DA, Lucas DM, Davis ME, De Lay MD, Johnson AJ, Guster SE, Freitas MA, Parthun MR, Wang D, Kulp SK, Grever MR, Chen C-S, and Byrd JC, “The Novel Histone Deacetylase Inhibitor OSU-HDAC42 Has Class I and II Histone Deacetylase (HDAC) Inhibitory Activity and Represents a Novel Therapy for Chronic Lymphocytic Leukemia”, American Society of Hematology, 2006.

13. De Lay MD, Johnson AJ, Lucas DM, Durr DT, Sass EM, Goettl VM, Lehman A, Jarjoura D, Grever MR and Byrd JC, "Early Fludarabine Treatment of TCL-1 Transgenic Mice Promotes Drug Resistance through a Mechanism Not Involving p53 Mutations: Implications for Patients with Chronic Lymphocytic Leukemia (CLL)", ASH Annual Meeting, 2007.

14. Lin TS, Fischer B, Blum KA, Andritsos LA, Jones JA, Moran ME, Broering S, Heerema NA, Lozanski G, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps M, Dalton JT, Grever MR and Byrd JC, "Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR)", ASH Annual Meeting, 2007.

15. Heerema NA, Byrd JC, Andritsos LA, Lozanski G, Blum K, Fischer B, Jones JA, Moran ME, Groering S, Schaaf LJ, Mahoney LS, Johnson AJ, Smith LL, Wagner AJ, Raymond CA, Phelps MA, Dalton JT, Grever MR and Lin TS, "Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts)", ASH Annual Meeting, 2007.

16. Lucas DM, Edwards RB, De Lay MD, West DA, Lozanski G, Johnson AJ, Salim AA, Lin TS, Byrd JC, Kinghorn AD and Grever MR, "The Plant-Derived Agent Silvestrol Has B-Cell Selective Activity In Vitro in Chronic Lymphocytic Leukemia Patient Cells and In Vivo in the Tcl-1 Mouse Model of CLL", ASH Annual Meeting, 2007.

17. Andritsos LA, Johnson AJ, Blum W, Kefauver C, Awan F, Smith LL, Lapalombella R, Wang D-S, Knight RD, Chen C-S and Byrd JC, "Unacceptable Toxicity of Lenalidomide When Administered to CLL Patients at Higher Doses", ASH Annual Meeting, 2007.

18. Johnson AJ, Smith LL, Raymond CA, Lucas DM, Flynn JM, Abu T, Malaz A, Statkevich P, Bannerji, R, Byrd JC. “The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia”, AACR 2008, Minisymposia Oral Presentation.

19. Lannutti BJ, Meadows SA, Kashishian A, Steiner B, May S, Johnson AJ, Ulrich RG, Yu A, Gallatin MW, Byrd JC, Puri KD, Giese NA, “CAL-101, a Potent Selective Inhibitor of the p110d Isoform of Phosphatidylinositol 3-Kinase, Attenuates PI3K Signaling and Inhibits Proliferation and Survival of Acute Lympoblastic Leukemia in Addition to a Range of Other Hematological Malignancies”, ASH Annual Meeting, 2008.

Updated 04/15/16

15

20. Lin TS, Heerema NA, Lozanski G, Fischer B, Blum KA, Andritsos LA, Jones JA, Flynn JM, Moran ME, Mitchell S, Johnson AJ, Phelps MA, Grever MR, Byrd JC. “Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities”, ASH Annual Meeting, 2008.

21. Wagner AJ, Hertlein EK, Raymond CA, West DA, Flynn JM, Lin T, Johnson AJ, Byrd JC. “17-DMAG Targets the NF-{kappa}B Family of Proteins to Induce Apoptosis in CLL: Clinical Implications of Hsp90 Inhibition”, ASH Annual Meeting, 2008. Oral Presentation.

22. May SE, Kashishian A, Lin TS, Jones JA, Flynn JM, Ulrich RG, Chen H, Yu AS, Puri KD, Lannutti BJ, Giese NA, Byrd JC, Johnson AJ. “CAL-101, a Selective Inhibitor of the p110{delta} Isoform of Phosphatidylinositol 3-Kinase, Effectively Induces Apoptosis in Primary Chronic Lymphocytic Leukemia Cells Providing a Novel Therapeutic Strategy for the Treatment of This Disease”, ASH Annual Meeting, 2008.

23. Chen S-S, Johnson AJ, Claus R, Sablitzky F, Plass C, Byrd JC. “Loss of Id4 Accelerates CLL Progression in TCL1 Mice”, ASH Annual Meeting, 2008.

24. Flynn JM, Johnson AJ, Andritsos L, Blum KA, Jones JA, Wiley EA, Hu W, Hessler J, Smith LL, Lucas DM, Small K, Statkevich P, Grever MR, Bannerji R, and Byrd JC. The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2009; 114:886.

25. Lannutti BJ, Meadows SA, Kashishian A, Steiner B, Pogosov G, Sala-Torra O, Johnson AJ, Byrd JC, Radich J, and Giese NA. CAL-101, An Oral p110 Selective Phosphatidylinositol-3-Kinase (PI3K) Inhibitor for the Treatment of B Cell Malignancies Inhibits PI3K Signaling, Cellular Viability and Protective Signals of the Microenvironment. Blood (ASH Annual Meeting Abstracts). 2009; 114:286.

26. Hertlein EK, Lin TS, Wagner JA , Towns H W, II, Goettl VM, Zhang X, Jarjoura D, Raymond CA, West DA, Byrd JC, and Johnson AJ. The HSP90 Inhibitor 17-DMAG Targets NF-κB to Induce Apoptosis in CLL and Prolongs Survival in a CLL Mouse Model. Blood (ASH Annual Meeting Abstracts). 2009; 114:732.

27. Maddocks K, Lapalombella R, Blum KA, Blum W, Fischer BB, Muthusamy N, Moran ME, Holtzapfel D, Byrd JC, Johnson AJ, and Andritsos L. Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2009; 114:3446.

28. Mahoney E, Johnson AJ, Wagner AJ, Hessler J, Gupta SV, Herman SEM, Andritsos L, Jones, JA, Flynn JM, Lucas DM, Grever MR, Byrd JC. Autophagy is a Relevant Cellular Process in CLL and Contributes to Drug Resistance of Flavopiridol. Blood (ASH Annual Meeting Abstracts). 2010, 116:691.

29. Woyach JA, Ruppert AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Byrd JC, Heerema NA. Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. Blood (ASH Annual Meeting Abstracts) 2010, 116:2456.

30. Blum KA, Jones JA, Andritsos L, Flynn JM, Deam D, Heerema NA, Phelps M, Johnson AJ, Grever MR, Byrd JC. Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood (ASH Annual Meeting Abstracts) 2010, 116:2472.

31. Stephens DM, Ruppers AS, Blum KA, Jones JA, Flynn JM, Johnson AJ, Ji J, Phelps M, Grever MR, Byrd JC. Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. Blood (ASH Annual Meeting Abstracts) 2010, 116:1378.

32. Herman SEM, Gordon AL, Mahoney E, Jaglowski SM, Blum KA, Buggy J, Hamdy A, Byrd JC, Johnson AJ. The Kinase Inhibitor, PCI-32765, Demonstrates Activity In Chronic Lymphocytic Leukemia Cells Independent of Microenvironmental Survival Signals. Blood (Ash Annual Meeting Abstracts) 2010, 116:1385.

33. Blum KA, Ruppert AS, Woyach JA, Jones JA, Andritsos L, Flynn JM, Rovin B, Villalona-Calero M, Ji J, Phelps M, Johnson AJ, Grever MR, Byrd JC. Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol. Blood (ASH Annual Meeting Abstracts) 2010, 116:1386.

Updated 04/15/16

16

34. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Poon J, Small K, Statkevich P, Grever MR, Bannerji R, Byrd JC. Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration. Blood (ASH Annual Meeting Abstracts) 2010, 116:1396.

35. Jones JA, Andritsos, Baiocchi RA, Benson Jr. DM, Blum KA, Christian B, Deam D, Flynn JM, Johnson AJ, Phelps MA, Porcu P, Byrd JC, Grever MR. Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma. Blood (ASH Annual Meeting Abstracts) 2010, 116:2834.

36. Herman SEM, Lapalombella R, Jones JA, Andritsos L, Gordon AL, Ramanunni A, Lannutti B, Muthusamy N, Byrd JC, Johnson AJ. Lenalidomide-Dependent Activation of the Phosphatidylinositol 3-kinase- Pathway Is Antagonized by CAL-101 In Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts) 2010, 116:1821.

37. Hofmeister CC, Bowers MA, Lee S, Phelps MA, Benson Jr. DM, Kraut EH, Hicks WJ, Deam D. Johnson AJ, Faraq Sh, Jones JA, Byrd JC. Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. Blood (ASH Annual Meeting Abstracts) 2010, 116:1933.

38. Johnson AJ, Smith LL, Wagner AJ, Hessler J, Flynn JM, Jones JA, Zhang X, Lehman A, Jarjoura D, Grever MR, Bannerji R, Byrd JC. Dinaciclib (SCH727965) Is a Novel Cyclin Dependent Kinase Inhibitor That Promotes Selective Apoptosis In CLL Cells and Abrogates the Protective Effects of Microenvironment Cytokines. Blood (ASH Annual Meeting Abstracts) 2010 116:971.

39. Hertlein EK, Yu L, Zhang J, Johnson AJ, Lucas DM, Marcucci G, Jarjoura D, Byrd JC. Micro-RNA and Gene Expression In CLL: Network Analysis Elucidating the Complex Role of the NF-B Signaling Pathway In Disease. Blood (ASH Annual Meeting Abstracts) 2010, 116:3642.

40. Harshman SW, Johnson AJ, Byrd JC, Freitas MA. A Novel Approach for Characterization Histone Isoform Distribution Across Cellular Compartments. American Society for Mass Spectrometry (Annual Meeting) 2011 Abstract #2090.

41. Byrd JC, Blum KA, Burger JA, Coutre SE, Sharman JP, Furman RR, Flinn IW, Grant BW, Richards DA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, O'Brien SM. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. ASCO Meeting Abstracts. 2011; 29:6508.

42. Flynn JM, Jones JA, Andritsos L, Blum KA, Johnson AJ, Hessler J, Wiley E, Heerema NA, Poon J, Small KA, Y. Jou, Zhang D, Statkevich P, Grever MR, Bannerji R, Byrd JC. Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. ASCO Meeting Abstracts. 2011; 29:6623.

43. Yang X, Hofmeister CC, Rozewski DM, Lee S, Chen P, Johnson AJ, Liu Z, Hade EM, Ji J, Schaaf LJ, Benson DM, Kraut EH, Hicks WJ, Chan KK, ChenC-S, Farag SS, Grever MR, Byrd JC, Phelps MA. The contribution of P-glycoprotein to clinical pharmacokinetic interactions between lenalidomide and temsirolimus. Cancer Research AACR Annual Meeting. 2011; 71:5473.

44. Johnson AJ, “CAL-101, a selective inhibitor of the p110 delta isoform of phosphatidylinositol 3-kinase, effectively induces apoptosis in chronic lymphocytic leukemia cells providing a novel therapeutic strategy”, NCI Translational Science Meeting, Washington, DC, July 28, 2011.

45. Lapalombella R, Ramanunni A, Yeh Y-Y, Wang L, Jha S, Staubli J, Herman SEM, Andritsos LA, Jones JA, Flynn JM, Mo X, Johnson AJ, Thompson P, Algate PA, Stromatt S, Freitas MA, Muthusamy N, Byrd JC. Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals. Blood (ASH Annual Meeting Abstracts). 2011; 118:622 (Oral presentation).

46. Rao R, Maddocks K, Johnson AJ, Chauhan L, Kambhampati S, Ganguly S, Reyes R, Aljitawi OS, Schorno K, Ford K, Dickman E, Byrd JC, Bhall KN. Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells. Blood (ASH Annual Meeting Abstracts). 2011; 118:929.

47. O'Brien S, Burger JA, Blum KA, Furman RR, Coutre SE, Sharman J, Flinn IW, Grant B, Heerema NA, Johnson AJ, Navarro T, Holmgren E, Hedrick E, Byrd JC. The Bruton's Tyrosine Kinase (BTK) Inhibitor

Updated 04/15/16

17

PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts). 2011; 118:983.

48. Blum KA, Wei L, Jones JA, Andritsos LA, Flynn JM, Heerema NA, Yang X, Rozewski D, Phelps M, Johnson AJ, Grever MR, Byrd, JC. Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial. Blood (ASH Annual Meeting Abstracts). 2011; 118:3910.

49. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer SM, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James DF, Lowe AM, Hedrick E, Byrd JC. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and oftaumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (ASCO Meeting Abstracts). 2012; 30:6508. (Oral presentation).

50. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Sharman JP, Flinn IW, Grant BW, Heerema NA, Johnson AJ, Navarro T, James DF, Hedrick E, O'Brien SM. The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (ASCO Meeting Abstracts). 2012; 30:6507. (Oral presentation).

51. Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frissora FW, Smith LL, Smucker KA, Flynn KM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells. Blood (ASH Annual Meeting Abstracts). 2012; 120:775. (Oral presentation).

52. Byrd JC, Furman RR, Coutre S, Flinn IW, Burger JA, Blum KA, Sharman J, Grant B, Jones JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Clow F, Kunkel L, James DF, O'Brien S. The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood (ASH Annual Meeting Abstracts). 2012; 120:189. (Oral presentation).

53. Woyach JA, Stefanovski MR, Goettl V, Ruppert AS, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Davis ME, Mao Y, Chang BY, Buggy JJ, Byrd JC, Johnson AJ. Global Inhibition of Bruton's Tyrosine Kinase (BTK) Delays the Development and Expansion of Chronic Lymphocytic Leukemia (CLL) in the TCL1 Mouse Model of Disease. Blood (ASH Annual Meeting Abstracts). 2012; 120:183. (Oral Presentation).

54. Maddocks K, Hertlein EK, Flynn JM, Andritsos LA, Wagner AJ, Chen TL, Phelps MA, Grever MR, Johnson AJ, Byrd JC, Jones JA. A Phase I Trial of the Intravenous (IV) Hsp90 Inhibitor 17-DMAG (alvespimycin) in Patients (pts) with Relapsed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). Blood (ASH Annual Meeting Abstracts). 2012; 120:1800.

55. E Mahoney, Cole SL, Maddocks K, Flynn JM, Jones JA, Zhang X, Byrd JC, Johnson AJ. Identification of Endoplasmic Reticulum Stress Inducing Agents by Antagonizing Autophagy: A New Potential Strategy for Identification of Anti-Cancer Therapeutics in B-Cell Malignancies. Blood (ASH Annual Meeting Abstracts). 2012; 120:2473.

56. Lapalombella R, Goettl V, Williams K, Tangeman L, Jha S, Dubovsky JA, Chappell DL, Johnson AJ, Sandanayaka V, Shechter S, McCauley D, Shacham S, Kauffman M, Byrd JC. Significant in Vivo Efficacy of the SINE KPT-330 in Mouse Models of CLL. Blood (ASH Annual Meeting Abstracts). 2012; 120:2452.

57. Hertlein EK, Chen TL, Claus R, Plass C, Lehman A, Jarjoura D, Maddocks K, Jones JA, Lucas DM, Johnson AJ, Byrd JC. The Hsp90 Inhibitor 17-DMAG Increases SOCS3 and Regulates Cytokine Production, Migration and Cell Death in Chronic Lymphocytic Leukemia. Blood (ASH Annual Meeting Abstracts). 2012; 120:1362.

58. Stephens DM , Stark A, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Changing The

Updated 04/15/16

18

Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype. Blood. (ASH Annual Meeting Abstracts) 2013; 122:2872.

59. Liu T-M, Ling YH, Phelps MA, Woyach JA, Hertlein EK, Towns WH, MacMurray J, Salunke SB, Chen C-S, Byrd JC, Johnson AJ. OSU-T315, An Integrin-Linked Kinase (ILK) Inhibitor, Induces Apoptosis By Targeting B Cell Receptor and CD49d Mediated AKT/ERK Activation In Chronic Lymphocytic Leukemia Cells. Blood. 2013 (ASH Annual Meeting Abstracts); 122:2523.

60. Flynn JM, Andritsos LA, Jones JA, Johnson AJ, Maddocks K, Wiley E, Small K, Im EK, Grever MR, Bannerji R, Byrd JC, Zhou H. Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 2013 (ASH Annual Meeting Abstracts); 122:871.

61. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SEM, Butchar JP, Cheney C, Zhang X, Buggy JJ, Muthusamy N, Levy R, Johnson AJ, Byrd JC. Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity. Blood. 2013 (ASH Annual Meeting Abstracts); 122:373.

62. O’Brien SM, Furman RR, Coutre SE, Flinn I, Burger JA, Blum KA, Sharman JP, Jones, JA, Wierda WG, Zhao W, Heerema NA, Johnson AJ, Tran A, Zhou C, Bilotti E, James DF, Byrd JC. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. J Clin Oncol. 2014 (ASCO Annual Meeting Abstract) 2014; 32:7014. (Oral presentation).

63. Godiwala NN, Maddocks KJ, Westbrook T, Byrd JC, Anderson BL, Johnson AJ. Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib. J Clin Oncol. (ASCO Annual Meeting Abstract) 2014; 32:7057.

64. Pierceall WE, Maddocks KJ, Wei EN, Chen C, Warner S, Doykan C, Lena R, Blake N, Cardone MH, Andritsos LA, Grever MR, Byrd JC, Trudel X, Johnson AJ. Distinct biomarkers as prognostic in chronic lymphocytic leukemia patients treated with alvocidib and Lenalidomide as single agents or combination regimens thereof. J Clin Oncol. (ASCO Annual Meeting Abstract) 2014; 32:7087.

65. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West J-S, Neuenburg J, James FJ, Johnson AJ, Byrd JC. A Phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with oftaumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. J Clin Oncol. (ASCO Annual Meeting Abstract) 2014; 32:7009.

66. Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. J Clin Oncol. (ASCO Annual Meeting Abstract) 2014; 32:7010.

67. Maddocks KJ, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. 2014 (European Hematology Association Biannual Conference) (Oral presentation).

68. Jones JA, MPH MD, Geyer, S, Andritsos LA, Awan F, Flynn JM, Maddocks KJ, Bingman A, Johnson AJ, Heerema NA, Brookfield C, Byrd JC, Grever MR. Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study. Blood. (ASH Annual Meeting Abstract)(Oral presentation).

69. Pollyea DA, Coutre S, Gore L, Adler M, Harris P, Phelps MA, Johnson AJ, Ling YH, Li H, Gutman JA, Byrd JC. A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Blood. (ASH Annual Meeting Abstract) (Poster presentation).

70. Guinn D, Ruppert AS, Maddocks KJ, Jaglowski S, Gordon AL, Lin TS, Larson RA, Marcucci G, Hertlein EK, Woyach JA, Johnson AJ, Byrd JC. Mir-155 Expression Is Associated with

Updated 04/15/16

19

Chemoimmunotherapy Outcome and Is Modulated by Bruton’s Tyrosine Kinase Inhibition with Ibrutinib. Blood. (ASH Annual Meeting Abstract) (Poster presentation).

71. Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ. Pharmacologic Inhibition with Duvelisib (IPI-145) and Genetic Inhibition of PI3K p110δ Antagonizes Intrinsic and Extrinsic Survival Signals in Chronic Lymphocytic Leukemia (CLL). Blood. (ASH Annual Meeting Abstract) (Poster presentation).

72. Zhong Y, Dong S, Thornton K, Mishra A, Porcu P, Bradshaw M, Bisconte A, Owens T, Verner E, Brameld K, Funk JO, Hill R, Johnson AJ, Dubovsky JA. Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. Blood. (ASH Annual Meeting Abstract) (Oral presentation).

73. Byrd JC, Furman RF, Coutre SE, Burger JA, Blum KA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Shaw Y, Bilotti E, Zhou C, James DF, and O'Brien S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent Ibrutinib. Blood. Feb 2015; DOI: http://dx.doi.org/10.1182/blood-2014-10-606038.

74. Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, Hamdy A, Ulrich RG, Byrd JC, Lannutti BJ, Johnson AJ. ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity. (2015 ASH Annual Meeting Abstract) (Poster presentation).

75. Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, Harrington BK, Covey T, Lannutti BJ, Izumi R, Ulrich RG, Byrd JC, Wiestner A, Johnson AJ, Woyach JA. The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia. (2015 ASH Annual Meeting Abstract) (Poster presentation).

76. Bottoni A, Rizzotto L, Lai TH, Mantel R, Simith L, El-Gamal D, Johnson AJ, Lapalombella R, Blachly JS, Byrd JC, Woyach JA, Sampath D. Targeting BTK By a microRNA Mechanism in Chronic Lymphocytic Leukemia. (2015 ASH Annual Meeting Abstract) (Poster presentation).

77. Hertlein EK, Chen TL, Lucas DM, Gupta N, MacMurray J, Goettl VM, Lehman AM, Johnson AJ, Byrd JC. NFkB p50 (Nfkb1) Contributes to Disease in the Eu-TCL1 Mouse Model of Chronic Lymphocytic Leukemia. (2015 ASH Annual Meeting Abstract) (Poster presentation).

78. Dong S, Byrd JC, Johnson AJ. Genetic Inhibition of PI3K p110delta Antagonizes Survival Signals and Induces Immune Activation in Chronic Lymphocytic Leukemia (CLL). (2015 ASH Annual Meeting Abstract) (Poster presentation).

79. Rogers KA, El-Gamal D, Harrington KB, Hing ZA, Goettl MV, Mantel, Smith LL, Yu L, Johnson AJ, Byrd JC, Lapalombella R, Woyach JA. The Eµ-Myc/TCL1 Transgenic Mouse as a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing. (2015 ASH Annual Meeting Abstract) (Poster presentation).

80. Long M, Beckwith KA, Maddocks KJ, Cheney C, Woyach JA, Johnson AJ, Muthusamy N, Byrd JC. Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients. (2015 ASH Annual Meeting Abstract) (Poster presentation).

Ongoing Research Support Active 5 R01 CA177292-03 Byrd /Johnson (Co-PI) 04/01/2013 – 03/31/2018 NCI Targeted Therapy for Lymphoid Malignancies Aim 1) To perform a phase II clinical trial of ibrutinib in relapsed and refractory CLL. Aim 2) To perform baseline and serial pharmacodynamic (PD) studies in the phase II ibrutinib study to determine if traditional genomic features, select BCR activation markers, and changes in miR marker expression are predictive for clinical response and 2-year PFS. Aim 3) To perform studies derived from samples from patients participating in both this and other single agent ibrutinib trials to determine the biologic features of tumor cells not cleared from the blood by 12 months and pharmacologic strategies for novel combination strategies to eliminate these. Role: Co-PI

Updated 04/15/16

20

5 R01 R01CA183444-03 Byrd/Johnson/Woyach (Co-PI) 01/01/2014 – 12/31/2018 NCI Molecular Evaluation of Targeted Therapies in Lymphoid Malignancies A Phase III clinical trial investigating ibrutinib alone or ibrutinib plus rituximab compared with standard therapy of bendamustine plus rituximab (BR) in older patients with previously untreated CLL. Role: Co-PI 1 R01 CA197870-01 (PI: Johnson / Woyach) 07/01/2015 – 06/30/2020 NCI Improving BTK Directed Therapy for CLL Aim 1: To perform pre-clinical work to support selective BTK inhibition with next-generation BTK inhibitor ACP-196 and this in combination with immunotherapy in CLL. Aim 2: To perform a Phase Ib study of ACP-196 in combination with obinutuzumab in relapsed and treatment naïve CLL and to evaluate associated pharmacokinetic and pharmacodynamic outcomes. Aim 3: To determine the most promising agents to treat CLL patients with acquired ibrutinib resistance due to C481 BTK mutations. 5 P01 CA081534-14 (SubK PI: Johnson) 09/24/2012 - 08/31/2017 NCI - Univ of California at San Diego Chronic lymphocytic leukemia research consortium – Project 6 To investigate drug resistance in CLL and identify new therapeutic agents through participation in the consortium. Role: PI, Project 6 5 UM1CA186712-02 Grever (PI) 0/01/2014 – 01/31/2019 NCI Experimental therapeutics of anti-cancer agents with Phase I emphasis This project encompasses a multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer. Role: Co-PI 5 P01 CA095426-13 (PPG Leader: Caligiuri) 09/30/2002 - 08/31/2017 NCI Innate Immunity: elucidation and modulation for cancer therapy. Project #1: Innate immune therapies in B-cell malignancies. The overall goal is to rapidly introduce innovative clinical trials testing laboratory-base hypotheses, while pursuing additional basic investigation of innate immunity for subsequent cancer immunotherapy trials. Role: Co-Investigator, Project 1 Completed Research Support 2003-2006 American Cancer Society-IDEC/Genentech/Ronald Levy Postdoctoral Fellowship Award LLS 7080-06 (PI: Byrd) 10/01/2005 - 09/30/2010 Leukemia & Lymphoma Society Experimental therapeutics in CLL - Project 1: Pre-Clinical and Clinical studies of Flavopiridol in CLL The central theme of this proposal is the pursuit of pre-clinical and clinical investigations of multi-targeted therapies for the treatment of genetically high risk CLL. Role: Co-Investigator 1 R21 CA133875-01 (PI: Blum) 7/15/2008 - 6/30/2010 NCI Modulating the tumor micro-environment in CLL using flavopiridol and lenalidomide

Updated 04/15/16

21

The goal of this project is to combine flavopiridol and lenalidomide for the treatment of patients with relapsed CLL. Role: Co-Investigator 2 P01 CA81534-06/ PO 10267714 06/01/2006 - 04/30/2011 NCI - Univ of California at San Diego Chronic lymphocytic leukemia research consortium Through participation in the consortium; to investigate drug resistance in CLL and identify new therapeutic agents. Role: Co-Investigator 5 K12 CA133250-02 (PI: Byrd) 09/09/2008 - 07/31/2013 NCI Translational Training Grant in Experimental Therapeutics Objective 1: To provide individualized faculty level training to ensure a cadre of translational medical doctors and basic science researchers who can collaborate with each other to design and implement hypothesis-driven experimental therapeutic research directed at patients with cancer. Objective 2: To provide applicants with a core course work of biostatistical, pharmacology, pharmacodynamic, clinical trial, grant writing, and professional education classes that will assure successful transition to faculty level positions focused on experimental therapeutics at academic NCI-designated cancer centers. Role: Paul Calabresi Scholar 5 P50 CA140158-03 (PI: Byrd) 08/17/2009 - 07/31/2014 NCI SPORE – Career Development Program The focus and goal of this application is highly translational research that improves our understanding of leukemia development, risk stratification and therapy. Role: CDP Scholar P01 CA81534 (SubK PI: Grever) 12/01/2011 - 11/30/2016 NCI - Univ of California at San Diego Chronic lymphocytic leukemia research consortium To investigate drug resistance in CLL and identify new therapeutic agents through participation in the consortium. Role: Co-Investigator Center for Clinical & Translational Science (CCTS) 02/11/2013 – 02/11/2014 The Ohio State University PO #20000025 Johnson (PI) 07/04/2013 – 07/03/14 Acerta Pharma BTK inhibitor study to determine if treatment with ACP-196 can reduce leukemia progression and increase survival in the transplant TCL1 transgenic mouse model of CLL 5 P50 CA140158-04 Byrd (PI) 08/17/2009 - 07/31/2015 NCE NCI SPORE - Experimental therapeutics of leukemia – Project 3: Lenalidomide as an Immune Modulating Agent for Chronic Lymphocytic Leukemia The focus and goal of this application is highly translational research that improves our understanding of leukemia development, risk stratification and therapy. Role: Co-PI, Project 3 Pending

Updated 04/15/16

22

None Overlap None